This variant is present at extremely low frequency in population databases (gnomAD v2.1: 4/282,282 alleles, AF=0.0014%; gnomAD v4.1: 62/1,613,818 alleles, AF=0.0038%; absent from gnomAD-Canada), meeting PM2 at supporting strength.¹ In silico predictors do not support a deleterious effect: REVEL score is 0.278, BayesDel is 0.13681, and SpliceAI predicts no splicing impact (max delta 0.02). However, these scores are insufficient to independently meet BP4.² This variant has been reported in ClinVar as Likely benign by one clinical laboratory (GeneDx) and as Uncertain significance by another (Labcorp/Invitae). No pathogenic classification has been asserted by any submitter.³ No functional studies, segregation data, de novo observations, or variant-specific publications were identified for this variant. OncoKB reports Unknown Oncogenic Effect with no curated functional evidence.⁴ With only one supporting-level pathogenic criterion (PM2) met and no benign criteria met, the evidence is insufficient to classify this variant as either pathogenic or benign. This variant is classified as a Variant of Uncertain Significance (VUS) under generic ACMG/AMP 2015 rules (PMID:25741868).⁵